Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Frequently asked questions
What sector does LIQUIDIA CORP. DL-001 (LT4) operate in?
LIQUIDIA CORP. DL-001 belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is LIQUIDIA CORP. DL-001 (LT4) current stock price?
As of the latest data, LIQUIDIA CORP. DL-001 stock price is €38.81, with a previous close of €39.83. LIQUIDIA CORP. DL-001 lost -€1.02 in the last trading session, representing a -2.56% loss.
What is LIQUIDIA CORP. DL-001 (LT4) current market capitalization?
LIQUIDIA CORP. DL-001 market cap is approximately 3.47 billion.
What is LIQUIDIA CORP. DL-001 (LT4) Earnings Per Share (EPS)?
The trailing EPS is €1.19.
What is LIQUIDIA CORP. DL-001 (LT4) Price-to-Earnings (P/E) ratio?
LIQUIDIA CORP. DL-001 current P/E ratio is 32.61.
What is LIQUIDIA CORP. DL-001 (LT4) EBITDA?
LIQUIDIA CORP. DL-001 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 77.39 million.
Does LIQUIDIA CORP. DL-001 (LT4) pay dividends?
No. LIQUIDIA CORP. DL-001 does not pay a dividend.
When is LIQUIDIA CORP. DL-001 (LT4) next earnings report?
LIQUIDIA CORP. DL-001 is expected to release its next earnings report on September 30, 2026.
What is LIQUIDIA CORP. DL-001 (LT4) beta (volatility) score?
LIQUIDIA CORP. DL-001 has a beta of 0.610, indicating lower volatility than the overall market.
